Prediction tools for unfavourable outcomes in Clostridium difficile infection: A systematic review

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Abou Chakra, Claire Nour ^a   Pepin, Jacques ^a   Valiquette, Louis ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER;

ADVERSE OUTCOME; AGE; CALIBRATION; CLINICAL PRACTICE; CLINICAL PREDICTION RULES; CLOSTRIDIUM DIFFICILE INFECTION; COCHRANE LIBRARY; DISEASE SEVERITY; EMBASE; HUMAN; INFORMATION RETRIEVAL; LEUKOCYTOSIS; MEDLINE; METHODOLOGY; MORTALITY; PREDICTION AND FORECASTING; QUALITY CONTROL; RECURRENT DISEASE; REPRODUCIBILITY; REVIEW; SAMPLE SIZE; SECONDARY ANALYSIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VALIDATION PROCESS; WEB OF SCIENCE; ALGORITHM; CLOSTRIDIUM DIFFICILE; DIGESTIVE SYSTEM EXAMINATION; EVALUATION; PHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PSEUDOMEMBRANOUS COLITIS; SENSITIVITY AND SPECIFICITY;

CLOSTRIDIUM DIFFICILE;

ALGORITHMS; BIOLOGICAL MARKERS; CLOSTRIDIUM DIFFICILE; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; SENSITIVITY AND SPECIFICITY;

EID: 84856187972     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030258     Document Type: Review

References (40)

1. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, et al. (2004) Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171: 466-472.
2. Dubberke ER, Reske KA, Noble-Wang J, Thompson A, Killgore G, et al. (2007) Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. Am J Infect Control 35: 315-318.
3. Indra A, Huhulescu S, Fiedler A, Kernbichler S, Blaschitz M, et al. (2009) Outbreak of Clostridium difficile 027 infection in Vienna, Austria 2008-2009. Euro surveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 14.
4. van Steenbergen J, Debast S, van Kregten E, van den Berg R, Notermans D, et al. (2005) Isolation of Clostridium difficile ribotype 027, toxinotype III in the Netherlands after increase in C. difficile-associated diarrhoea. Euro surveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 10 (7): E050714.050711.
5. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, et al. (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31: 431-455.
6. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, et al. (2007) Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 28: 140-145.
7. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, et al. (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364: 422-431.
8. Golan Y, Louie T, Miller M, Mullane KM, Weiss K, et al. (2011) Risk of recurrence and time to recurrence following treatment of Clostridium difficile infection: patient characteristics and the differential effect of fidaxomicin vs vancomycin. Gastroenterology 140: S360-S361.
9. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, et al. (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362: 197-205.
10. Altman DG, Lyman GH, (1998) Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52: 289-303.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 3: e123-e130.
12. Bartlett JG, Chang T, Taylor NS, Onderdonk AB, (1979) Colitis induced by Clostridium difficile. Reviews of Infectious Diseases 1 (2): 370-378.
13. Chang TW, Bartlett JG, Gorbach SL, Onderdonk AB, (1978) Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infection & Immunity 20: 526-529.
14. Laupacis A, Sekar N, Stiell IG, (1997) Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA 277: 488-494.
15. McGinn TGMD, Guyatt GHMD, Wyer PCMD, Naylor CDMD, Stiell IGMD, et al. (2000) Users' Guides to the Medical Literature: XXII: How to Use Articles About Clinical Decision Rules. JAMA 284: 79-84.
16. May S, Rosedale R, (2009) Prescriptive clinical prediction rules in back pain research: a systematic review. J Man Manip Ther 17: 36-45.
17. Na X, Martin AJ, Leffler DA, Flores SL, Kyne L, et al. (2011) Derivation and validation of a clinical prediction tool for severe Clostridium difficile infection. Gastroenterology 140: S-326-S327.
18. Zilberberg MD, Shorr AF, Micek ST, Doherty JA, Kollef MH, (2009) Clostridium difficile-associated disease and mortality among the elderly critically ill. Critical Care Medicine 37: 2583-2589.
19. Bhangu S, Bhangu A, Nightingale P, Michael A, (2010) Mortality and risk stratification in patients with Clostridium difficile-associated diarrhoea. Colorectal Disease 12: 241-246.
20. Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, et al. (2007) Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. Journal of Infection 55: 495-501.
21. Velazquez-Gomez IMD, Rocha-Rodriguez RMD, Toro DHMDFA, Gutierrez-Nunez JJMDF, Gonzalez GMD, et al. (2008) A Severity Score Index for Clostridium difficile Infection. Infectious Diseases in Clinical Practice 16: 376-378.
22. Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, et al. (2009) Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136: 1206-1214.
23. Welfare MR, Lalayiannis LC, Martin KE, Corbett S, Marshall B, et al. (2011) Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect.
24. Rubin MS, Bodenstein LE, Kent KC, (1995) Severe Clostridium difficile colitis. Diseases of the Colon & Rectum 38: 350-354.
25. Fujitani S, George WL, Murthy AR, (2011) Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 32: 220-228.
26. Toro DH, Amaral-Mojica KM, Rocha-Rodriguez R, Gutierrez-Nunez J, (2011) An innovative severity score index for clostridium difficile infection: A prospective study. Infectious Diseases in Clinical Practice 19 (5): 336-339.
27. Hu MY, Maroo S, Kyne L, Cloud J, Tummala S, et al. (2008) A prospective study of risk factors and historical trends in metronidazole failure for Clostridium difficile infection. Clin Gastroenterol Hepatol 6: 1354-1360.
28. Drew RJ, Boyle B, (2009) RUWA scoring system: a novel predictive tool for the identification of patients at high risk for complications from Clostridium difficile infection. Journal of Hospital Infection 71: 93-94; author reply 94-95.
29. Knaus WA, Draper EA, Wagner DP, Zimmerman JE, (1985) APACHE II: a severity of disease classification system. Crit Care Med 13: 818-829.
30. Lungulescu OA, Cao W, Gatskevich E, Tlhabano L, Stratidis JG, (2011) CSI: a severity index for Clostridium difficile infection at the time of admission. J Hosp Infect.
31. Im GY, Modayil RJ, Feuerman M, Lin CT, Balani AR, et al. (2011) A prediction model of disease severity in Clostridium difficile-associated disease. Gastroenterology 140: S361.
32. McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L, (2005) A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 40: 265-272.
33. Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, et al. (2006) Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 43: 411-420.
34. Gujja D, Friedenberg FK, (2009) Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther 29: 635-642.
35. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB, (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45: 302-307.
36. Ebell MH, (2001) Evidence-based diagnosis. New York, Inc: Springer-Verlag.
37. Deeks J, Altman D, (2004) Diagnostic tests 4: likelihood ratios. BMJ 329: 168-169.
38. Johnson S, (2009) Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. Journal of Infection 58: 403-410.
39. Garey KW, Sethi S, Yadav Y, DuPont HL, (2008) Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. Journal of Hospital Infection 70: 298-304.
40. Justice AC, Covinsky KE, Berlin JA, (1999) Assessing the generalizability of prognostic information. Ann Intern Med 130: 515-524.